Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Dr. Hoos Discusses Key Points of the Ipilimumab Trial

Axel Hoos, MD, PhD
Published: Wednesday, Jun 15, 2011



Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses key points of the ipilimumab phase III trial looking at patients with untreated metastatic melanoma; a separate trial studied pretreated patients. The trial looked at the long-term survival in patients treated with ipilimumab with or without combination with dacarbazine. The combination therapy was more successful in terms of a survival benefit. Patients saw durable responses in the form of a shrinking tumor size for a median of 19 months compared to 8 months in the control; a PFS survival was also noted.
SELECTED
LANGUAGE


Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb discusses key points of the ipilimumab phase III trial looking at patients with untreated metastatic melanoma; a separate trial studied pretreated patients. The trial looked at the long-term survival in patients treated with ipilimumab with or without combination with dacarbazine. The combination therapy was more successful in terms of a survival benefit. Patients saw durable responses in the form of a shrinking tumor size for a median of 19 months compared to 8 months in the control; a PFS survival was also noted.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x